Since an increase in the levels of IL-6 has been described as a consequence of the overactivation of the immune system in COVID-19 patients, the use of a blocker for such interleukin was suggested in order to limit the inflammatory process triggered by the virus [10–12]. The gene discussed is IL6; the disease is COVID-19.